George Lundberg, MD Editor in Chief at Cancer Commons

  • December 2, 2019  

    FDA Approves Acalabrutinib for CLL/SLL as Part of Project Orbis Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    In an unusual collaboration between the U.S. Food and Drug Administration (FDA), Canada, and Australia, acalabrutinib (Calquence) has been approved as another first line therapy for chronic lymphatic leukemia/small cell lymphoma.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    FDA Approves Therapy to Treat Patients with Relapsed and Refractory Mantle Cell Lymphoma Supported by Clinical Trial Results Showing High Response Rate of Tumor Shrinkage Bookmark

    George Lundberg, MD

    Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

    Of the non-Hodgkin lymphomas, mantle cell lymphoma can be especially difficult to treat. The FDA has now announced accelerated approval for the drug zanubrutinib (Brukinsa) after it showed strong effects for patient in single-arm clinical trials.

    Go to full article published by the U.S. Food and Drug Administration (FDA).

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • December 2, 2019  

    Biological Activity of Weekly ONC201 in Adult Recurrent Glioblastoma Patients Bookmark

    George Lundberg, MD

    Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    This paper reports the results of an investigation of the drug ONC201 in adults with recurrent glioblastoma (GBM). It found that ONC201 penetrated the blood-brain barrier and achieved intratumoral levels without toxicity. While most GBMs were not responsive, one patient with the mutation H3 K27M experienced a prolonged remission.

    Go to full paper published in Neuro-Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • November 12, 2019  

    Researchers Discover Coffee Drinkers Could Halve their Risk of Liver Cancer Bookmark

    George Lundberg, MD

    Article from Medical Xpress curated by Editor in Chief George Lundberg, MD, who notes: 

    Association is not causation. Yet, when the numbers are very high indeed, and the differences stark,  one had best take them seriously. People in the U.K. who drink coffee are half as likely to develop liver cancer, all known confounders considered.

    Go to full article published by Medical Xpress.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • November 12, 2019  

    Novel Agents Influence the Development of New Strategies for Treatment of Bladder Cancer Bookmark

    George Lundberg, MD

    Article from Targeted Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

    Once bladder cancer has infiltrated the muscle wall in elderly patients, it becomes challenging to treat. New drugs and immunotherapies show some promise.

    Go to full article published by Targeted Oncology.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • November 12, 2019  

    FDA Approves Test for Late-line HRD+ Ovarian Cancer Bookmark

    George Lundberg, MD

    Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

    A new diagnostic test and new therapeutic drugs have received approval from the U.S. Food and Drug Administration (FDA) for certain advanced ovarian cancers, which are always difficult to treat.

    Go to full article published by Cancer Network.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • November 12, 2019  

    ADMIRAL: Gilteritinib vs Chemotherapy in Relapsed or Refractory FLT3-Mutated AML Bookmark

    George Lundberg, MD

    Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

    A clinical trial showed substantial benefits of progression-free survival and overall survival for patients with a particular form of acute myeloid leukemia when treated by gilteritinib versus chemotherapy. However, the disease was still fatal.

    Go to full article published by The ASCO Post.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • November 12, 2019  

    Less Invasive Surgery Wins in Esophageal Cancer Bookmark

    George Lundberg, MD

    Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

    Minimally invasive surgery for esophageal cancer produces similar outcomes with fewer complications than open surgery. A reduction in pulmonary atelectasis may underlie these findings.

    Go to full article published by MedPage Today.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • November 12, 2019  

    Ovarian Cancer: Pathogenesis and Current Recommendations for Prophylactic Surgery Bookmark

    George Lundberg, MD

    Research paper from the Journal of the Turkish-German Gynecological Association curated by Editor in Chief George Lundberg, MD, who notes: 

    Since many ovarian cancers arise in the adjacent fallopian tube, 20-40% of ovarian cancer can be prevented by prophylactic salpingectomy.

    Go to full paper published in the Journal of the Turkish-German Gynecological Association.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

  • November 12, 2019  

    Microwave Ablation Feasible for cT1b Renal Cell Carcinoma Bookmark

    George Lundberg, MD

    Article from Renal and Urology News curated by Editor in Chief George Lundberg, MD, who notes: 

    Microwave ablation has been shown to be a viable alternative to both radical and partial nephrectomy for kidney cancers that measure less than 7 cm in diameter. Outcomes for the two approaches are comparable.

    Go to full article published by Renal and Urology News.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.